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The unique status of first-in-human
studies: strengthening the social value
requirement
Michelle G.J.L. Habets, habets@law.eur.nl, Johannes J.M. van Delden and Annelien L. Bredenoord
For clinical research to be ethical, risks need to be balanced by anticipated benefits. This is challenging
for first-in-human (FIH) studies as participants are not expected to benefit directly, and risks are
potentially high. We argue that this differentiates FIH studies from other clinical trials to the extent that
they should be given unique status in international research ethics guidelines. As there is a general
positive attitude regarding the benefits of science, it is important to establish a more systematic method
to assess anticipated social value to safeguard participants not only from enrolling in risky, but also in
futile trials. Here, we provide some of necessary steps needed to assess the anticipated social value of the
intervention.
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The recent tragedy in Rennes is a reminder of the
dangers of first-in-human (FIH) studies. After
taking the experimental, candidate drug BIA10-
2474, designed to deal with pain, mood disor-
ders, and anxiety, one healthy volunteer died
and four other men may have permanent brain
damage. Although tragic events like these are
fortunately rare, it is indisputable that research
participants in FIH studies are exposed to po-
tential (serious) harm, both predictable as well as
unexpected. FIH studies form the foundation of
the bridge that crosses the translational valley of
death: ‘the widening gap between advances in
basic science and the practical application of
that knowledge’ [1]. They are designed to eval-
uate the risks and tolerability as well as the
Maximum Tolerated Dose (MTD) of a drug or
intervention. In subsequent trials, risks are
lower, because severe harm with a high rate of1359-6446/ 2016 The Authors. Published by Elsevier Ltd. This is an o
http://dx.doi.org/10.1016/j.drudis.2016.11.016 recurrence will, in all likelihood, have been un-
covered in the FIH study.
Until the disaster in the Northwick park trial in
2006, where six healthy volunteers exposed to
TGN1412 were hospitalized with multi organ
failure, there was a lack of specific regulatory
guidance on FIH trials [2]. The tragic outcome of
this FIH study was a wakeup call for pharma-
ceutical companies and regulatory agencies. The
cytokine storm induced by this monoclonal
antibody made it clear that methods to assess
risks for traditional small molecule drugs were
not sufficient for new biologics. Several regula-
tory guidelines specific for FIH studies have been
issued after the Northwick park event [3–5] to
standardize the identification and mitigation
of potential risks (known probabilities of harm
with a certain magnitude) and uncertainties
(unknown probability of known risk). However,
this is more difficult to determine for complexpen access article under the CC BY license (http://creativecommons.org/innovative interventions, such as biologics and
emerging technologies. For example, pluripo-
tent stem cells-derived interventions bring ad-
ditional concerns because of the ex vivo
cultivation of cells, possibly leading to contam-
ination of cells or genetic aberrations in the cell
line due to the selection procedure of rapidly
proliferating cell lines. Moreover, accidental
transplanted non-differentiated stem cells can
cause teratomas. In addition to these risks and
uncertainties, for innovative health interven-
tions, unpredictable adverse reactions or ‘un-
known unknowns’ (ignorance) may also occur at
a higher rate [6]. Due to a lack of precedent for
these complex innovative interventions, re-
search subjects are exposed to more uncertainty
and ignorance. Additionally, there is an increased
risk because of the invasive and often irreversible
insertion of these innovative interventions, and
the limited predictability of animal models [7].licenses/by/4.0/).
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FIH studies under the same umbrella, when
examining complex innovative interventions in
FIH studies, greater precautionary measures
should be exercised in the design of the FIH
study compared to subsequent trials.
For research to be ethical, risks need to be
balanced by benefits [8]. However, FIH studies
are not designed to provide a therapeutic ben-
efit for research participants, which is most ev-
ident when healthy volunteers are enrolled.
Therefore, although it might not be excluded
that a medical benefit does occur, this cannot be
the justification for enrolling individuals. Instead,
the justification needs to be found in the an-
ticipated social value of the intervention [8,9].
Unfortunately, no guidance is given in ethical
and regulatory guidelines on how to assess the
anticipated social value [9]. Our aim in this paper
is to provide some of the necessary steps needed
for assessing the anticipated social value of
interventions.
Balancing potential harm and anticipated
social value in FIH studies
Similar to risks, uncertainty exists whether con-
ducting FIH studies will lead to any benefits in
future. However, whereas for uncertainty relating
to risks, Research Ethics Committees (REC) and
researchers usually use the precautionary prin-
ciple, for uncertainty in benefits of science, a
general disposition exists ‘towards hopefulness
or confidence of success’, which Barke has la-
belled the sanguinity principle [10]. This princi-
ple is the counterpart of the precautionary
principle. Whereas for risks, the burden of proof
to show that harm will not take place lies on the
individuals that want to do the research; for
benefits, the burden of proof to show that sci-
ence will not provide a benefit, seems to lie on
the shoulders of those who would reject doing
the research [10]. Indeed, researchers, but also
the public, have a positive view on the societal
benefits of medical science [10]. A survey in the
US in 2008 found a positive public attitude about
science and technologies, across all demo-
graphics, and more than 50% of the public
agreed with the statement that the benefits of
scientific research have strongly outweighed its
harmful effects, and 87% expressed support for
government funding [11].
In contrast to this positive attitude, based on
recent data, we can actually be fairly certain that
most interventions tested in clinical trials will not
lead to any societal benefit. Indeed, the success
rate of interventions entering FIH studies is very
low; only about 8–10% of interventions in FIH
studies lead to market authorization [12,13].472 www.drugdiscoverytoday.comIncidentally, it has been estimated that less than
8% of these approved drugs offer an increased
therapeutic benefit over existing drugs [14].
Many participants thus enrol in trials that will not
lead to benefits for society; in addition, one study
demonstrated that about 15% of marketed au-
thorized drugs are more harmful than beneficial
[14]. Whether these numbers are widespread is
not known, however, a worrisome report from
the US Government Accountability Office in
January 2015, revealed that ‘. . .[proble-
[problems]. . .have prevented the FDA from
publishing statutorily required reports on certain
potential safety issues and post market studies in
a timely manner, and have restricted the agen-
cy’s ability to perform systematic oversight of
post market drug safety’ [15]. As post market
evaluation of medical interventions is apparently
not up to date, exact knowledge on how many
interventions are harmful is lacking.
At this point, one could of course argue that
there are many different ways, besides market
authorization of the tested intervention, in which
a trial can be valuable. For example, Kimmelman
has distinguished various ways a FIH study can
be valuable: it can motivate further preclinical
studies (reciprocal value); it can lead to modifi-
cations in the trial itself when repeated (iterative
value) and it can even provide useful knowledge
for other interventions in the drug pipeline
(collateral value) [16]. We do not deny that
important knowledge can be obtained from FIH
studies independent of eventual market autho-
rization of the intervention; however, when
finding a justification for enrolling humans in a
FIH study it should not be mere knowledge. The
risks and uncertainties to the research partici-
pants should be balanced by the anticipated
social value of the intervention. It is the inter-
vention that will benefit future patients. More-
over, this is a prospective evaluation; what is
important is how the intervention may change
the lives of (future) patients. Any possible, un-
foreseen, important knowledge should not
weigh in the decision to approve a trial in a
prospective evaluation.
By design, FIH studies assess potential harm to
future patients, and by design, they rarely pro-
vide a therapeutic benefit to participants, and in
reality, they most often do not lead to future
market authorization of the examined inter-
vention. Although subsequent trials may neither
provide a benefit to participants (nor lead to
market authorization), what makes these trials
different, is the expectation of a possible benefit to
the participant. Researchers need to be agnostic
about future improvement or decline in patients’
wellbeing, when comparing a new interventionwith the standard of care. Phase II and III trials are
designed to allow for patient-participants (never
healthy volunteers) to benefit. Potential harm
should be balanced with the anticipated social
value of the intervention, and potential thera-
peutic benefit. Moreover, in theory, the risks are
reduced in phase II and III trials. For these rea-
sons, FIH studies are ethically distinct from other
trials, and we believe making this explicit in
guidelines on ethical principles is important for
two reasons; first, FIH studies should be assessed
differently by researchers and RECs; second, FIH
participants are in need of additional protection,
due to the type of research. Thus, although
specific regulatory guidance is available to
standardize the identification and mitigation of
potential risks in FIH studies [3–5], we argue for
recognizing the unique status of FIH studies
among clinical trials in international guidelines
on ethical conduct in clinical research. In a similar
manner, as for example, CIOMS has guidelines
specifically for women, children and adolescents,
and vulnerable persons, we argue for a separate
guideline for FIH study participants, as they too,
are more vulnerable than participants in sub-
sequent trials [17].
Participants need additional safeguarding
In the following sections we will discuss several
ways to safeguard research participants in FIH
studies. Of course, risk assessment and risk
minimization is the most vital way to protect
participants. However, here, we are interested in
ways to safeguard humans from enrolling in
futile FIH studies. For that purpose, we will first
provide some necessary, although not exhaus-
tive, steps to assess the anticipated social value
of the intervention. This is important because
RECs have no common language to consider nor
a common approach to assess these benefits in
human research [18], and simultaneously, they
will also be led by the sanguinity principle (they
are hopeful of success).
First safeguard: accurate assessment of
the anticipated social value of the
intervention
When assessing the anticipated social value of
the intervention, we need to follow at least the
following three steps.
Step 1. Estimating the pharmacological
effect in humans
In a first step, researchers and RECs need to
estimate the nature and magnitude of the
pharmacological (pharmacodynamics and
pharmacokinetics) effect the intervention will
have in humans. This prediction will be made in
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efficacy. Correct evaluation of preclinical data is
very important. However, increasingly, reports
are published about the inadequacy of preclin-
ical research, for example, methodological flaws
[19] such as lack of randomization and blinding
[20] and inadequate statistical analysis in
reporting [7]. Publication bias of preclinical trials
has also been found [19]. Often, disciplines have
a preferred animal species based on costs, ease
of use, habit, and reproductive capacity [21].
Several suggestions have been made to
improve the predictability of animal studies and
thus to provide additional safeguards for FIH
participants; for example having a central reg-
ister for animal trials, in a similar manner as is
already the case for clinical trials [7]; minimum
standards for range and quality of animal data
before translation can take place [22]; rigorous
methods such as blinding and random assign-
ment [19,22]; broadening the preclinical evi-
dence by looking at reference classes [23],
routinely conducting systematic reviews [24],
but also plain transparency, standardization,
uniform reporting, replication, as well as unbi-
ased selection and publication of preclinical data
[20,24–28]. Simultaneous, however, the predict-
ability of animal models is much less reliable for
emerging technologies, such as nanotechnolo-
gy, than for traditional molecules [27]. Possibly,
iPSC cell tissue could help predict the pharma-
codynamics and pharmacokinetics of preclinical
interventions in humans. As these cells are not
only human, but can also be patient specific,
they will be good predictors for the impact of
interventions on cells.
After evaluating the preclinical data to esti-
mate the nature and magnitude of efficacy of an
intervention in animal models, Kimmelman and
Henderson argue that the likelihood of efficacy
inferred from preclinical trials should be adjusted
by comparing the intervention to similar inter-
ventions in the same reference class that have
already been tested in FIH studies [30]. For
example, in the case of stroke, none of the
interventions studied in animal models were
shown to be efficacious in human trials. So far,
this has not led to changing the commonly used
animal model for preclinical research in stroke
[18,31]. When researchers and RECs need to
assess a stroke intervention, they should take
this information into account [30]. Results of
preclinical trials therefore need to be publicly
available; compulsory publication in a
database would give researchers, RECs, and the
scientific community as a whole, an opportunity
to scrutinize these data before translation takes
place.As RECs have difficulties interpreting elaborate
preclinical trial data [32], it may be well worth
designing training programs for REC members
[29]. These trainings could be focussed on de-
cision-making in data poor settings in the
presence of uncertainty [33]. Principles for fa-
cilitating decision-making need to be developed.
This could be done by establishing specialized
working groups within the FDA or EMA [29].
Step 2. The anticipated clinical
improvement of the patient
Assuming that the intervention will be effica-
cious, the next step is to assess whether the
intervention will also lead to a clinical im-
provement for patients. Even if efficacy in sur-
rogate endpoints is expected, based on
preclinical data, this may not lead to an im-
provement in patients’ wellbeing. A reduction in
tumour size may, for example, not lead to an
improvement in quality of life, or life extension.
In addition, assessing a clinical improvement
consists of weighing the anticipated pharma-
cological effect against factors that may prevent
the intervention from improving (future)
patients’ wellbeing. The most important cause
may be adverse drug reactions. For example, the
infamous drug thalidomide, used in the 50’s to
treat morning sickness, caused thousands of
disabled babies to be born. The drug was
banned from the market; however, at the mo-
ment, thalidomide seems a promising drug for
children with TB meningitis resistant to routine
medication [34]. For these patients, the risks of
adverse side effects may be worth taking, as the
disease can be fatal (and pregnancies while on
the drug, can be avoided). Unfortunately, we
often do not know the risks.
Other aspects that are important, and may be
predictable, are the duration of the pharmaco-
logical effect, as well as the ease of use. Can we
predict by, for example, the manner of applying
the intervention whether patients will want to
use the drug? For life saving medication, burdens
and side effects can be high; for other medica-
tion, many factors are relevant to patients when
deciding whether they will make use of a mar-
ket-approved medication.
Step 3. The anticipated social value of the
intervention
Once clinical improvement is anticipated, it
needs to be assessed on a societal level. As social
value is an ambiguous concept, we have pro-
posed in previous work to limit the concept of
social value to the nature and magnitude of the
improvement the intervention is expected to
have on the wellbeing of patients, individuals insociety, or society [9]. Although knowledge
gained from clinical trials can be very important,
we believe that to enrol participants in high-risk
FIH studies, a reasonable expectation of social
value of the intervention needs to be present
before enrolling them. We cannot justify FIH trials
retrospectively. Ultimately, it is the intervention
or the application of the knowledge that will
have value for society. The anticipated social
value is the clinical benefit to patients, relative to
the already market approved availability of al-
ternative interventions, number of patients,
disease severity, and coverage in health insur-
ance.
Although it is the task of both researchers and
RECs to weigh possible harm to research parti-
cipants with anticipated social value, outside of
this risk-social value analysis, it is hard to de-
termine what has anticipated social value. We
have previously argued, that it is the public at
large that needs to decide what contributes to
social value. Is it number of patients affected by a
disease, severity of disease, quality of life or other
aspects? This could be done, for example,
through funding agencies that set up (part of )
their research agenda based on political deci-
sions regarding societal challenges that require
research programs [9].
It is important to be aware that we have not
assessed the FIH study itself, only the maximum
value that (future) patients or society can gain
from the intervention that will be examined. The
evaluation of the intervention precedes the as-
sessment of the trial, as it is a prerequisite that
the intervention is anticipated to have social
value.
Of course, it is also important to evaluate the
trial itself; what is the translational prospect of
the study; and what is the validity of the study
design, but we have discussed this elsewhere [9].
Second safeguard: transparency of data
A second approach to prevent research partici-
pants from enrolling in futile FIH studies, is
maximizing knowledge on trials and interven-
tions, and thus abandoning the secrecy of safety
and efficacy data by pharmaceutical companies,
researchers and the FDA. The US Food and Drug
Administration Amendments Act only require
results of clinical trials examining FDA approved
interventions, to be published on clinicaltrials.-
gov, one year after the end of the trial. Com-
pliance with this is extremely low. STAT
investigated compliance of pharmaceutical
companies in 9000 trials in clinicaltrials.gov and
found only two entities that complied with
reporting requirements more than half of the
time (http://www.statnews.com/2015/12/13/www.drugdiscoverytoday.com 473
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ency for its own sake could be an ethical re-
quirement, it is also important for protecting
research participants.
In the aftermath of the tragic events in Rennes,
it became clear that multiple pharmaceutical
companies had (already) evaluated FAAH1 inhi-
bitors as possible treatments for pain, mood
disorders, and other medical problems; for ex-
ample, Pfizer has tested their FAAH1-inhibitor PF-
04457845 in six clinical trials who are all either
completed or terminated (clinicaltrials.gov (PF-
04457845)); Ironwood Pharmaceuticals, Inc. has
completed one trial (clinicaltrials.gov (IW-6118));
and Sanofi completed one, and terminated an-
other trial (clinicaltrials.gov (SSR411298)) [35].
Unfortunately, on clinicaltrial.gov no results can
be found yet, but see [36,37]. Although there is a
general duty to register clinical trials, some of the
policy Acts make exceptions for phase I trials
[38]. As a consequence, it is possible that more
individuals than necessary may enrol in trials due
to repetitive studies, exposing them to potential
risks. Moreover, with the current policy,
researchers cannot learn from each other’s neg-
ative results, or build upon others’ knowledge,
delaying scientific understanding. This can lead
to individuals enrolling in futile trials, in spite of
the evidence of non-efficacy being available. In
addition, keeping data secret breaks the social
contract, a hypothetical agreement, with research
participants who may have enrolled for altruistic
reasons (Michael McDonald, pers. commun.). Last,
the lack of an obligation to make results public,
has led to a well-recognized problem of biased
publication of data of clinical trials.
Recently, the International Committee of
Medical Journal Editors proposed plans for
making data sharing of clinical trials a require-
ment for publication in ICMJE member journals,
and all other journals that will follow their rec-
ommendation [39]. These positive develop-
ments may be undermined by the increase in
industry sponsorship, as this is associated with
changes in the disclosure behavior of academic
researchers. These researchers are ‘subject to
more stringent contract terms that restrict
publication disclosure through delay and se-
crecy’ [40]. Moreover, published studies spon-
sored by industry are more likely to have
industry-favoring outcomes [41,42].
At the very least FIH studies should require
registration in a publicly available database, as is
already the case for phase II, III and IV. Also
compulsory for other phases since the US Food
and Drug Administration Amendment Act of
2008, is revealing sponsor-imposed publication
restrictions, when employees other than the474 www.drugdiscoverytoday.comsponsor, publish results [43]. Unfortunately,
these publication restrictions are now made after
trial results are published. We agree with Stretton
and colleagues that these restrictions should be
made available before participants enrol, in the
informed consent form [43]. This is necessary for
participants to make an informed decision. In-
deed, the general lack of transparency in in-
formed consent forms about whether results are
required to be published or can be kept quiet,
could be seen as unethical.
Third safeguard: direct benefits in FIH
studies
A last recommendation to safeguard research
participants, is for FIH trials to initiate testing for
efficacy, besides the potential risks. Especially for
interventions of currently untreatable diseases
that give rise to a high morbidity or mortality, it
may be desired to design studies to allow at least
a minimal chance of direct benefits. This can be
done by using what is expected to be a thera-
peutic dose, instead of starting with sub thera-
peutic levels, and by enrolling patients able to
benefit, instead of refractory patients. This would
be a way to circumvent participants from en-
rolling in trials for the prospect of generating
scientific knowledge alone, which, we have ar-
gued, can never justify exposure to risks and
burdens of invasive interventions. Indeed,
patients with an open therapeutic window have
the possibility to benefit therapeutically,
whereas healthy research subjects and often,
refractory patients, cannot.
Elsewhere, we have provided arguments for
assessing, as well as restricting, efficacy in FIH
studies (submitted). Briefly, trade-offs can exists
between, for example, the optimal trial design to
provide a potential direct benefit and the opti-
mal trial design to reduce risks. For instance, in a
phase I study with Amyotrophic Lateral Sclerosis
(ALS) patients, the choice was made to inject
neural stem cells within the lumbar spinal cord,
as this was safer than injecting them at the level
of the cervical spine, which would have been
able to provide the participants the potential to
benefit [44]. Safety of the participants should
always stay the primary focus of researchers. In
addition, testing efficacy as an additional end-
point should never be used to evade the stricter
regulation of non-therapeutic trials (submitted).
Only under specific circumstances should effi-
cacy be examined as an additional endpoint to
safety in FIH studies.
Conclusion
Here, we have demonstrated that the ethical
challenges of FIH studies are more complex thanother clinical trials, and, as a consequence, FIH
studies should be accorded unique status in
ethical guidelines. Moreover, research partici-
pants that enrol in these studies need additional
safeguarding to the conditions they are in
[45,46]. Whereas uncertainties in risks-assess-
ment have been addressed in the literature, this
is much less the case for uncertainties regarding
the benefits of research. We argue that identical
to safeguarding participants from uncertainties
in harm, we should safeguard FIH research
participants from uncertainties in benefit, pre-
venting them from enrolling in studies that are
likely to be futile. In order to do this, we need a
systematic way to assess the anticipated social
value of the intervention tested. Here, we have
provided some necessary steps for this assess-
ment. It is important for researchers, RECs,
funding agencies and the public at large to
initiate a debate on social value. Moreover, as
many before us have argued, transparency in
clinical research is key.
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